Novel Immune Strategies to Enhance Beta cell Replacement Therapies for T1D 2021
Topic: Letters of intent (LOI's) are sought for preclinical and/or clinical studies from academic or industry applicants with innovative and incremental immune modulation and engineering approaches aiming to effectively subvert and/or modulate undesired immune reactivity against implanted cells products towards more tolerogenic responses in vivo. Collaborations including complementary expertise i.e. bioengineers, immunologists, cell biologists, transplant researchers, are highly encouraged and will be prioritized. Only projects with relevance to T1D will be considered.
Founder: Juvenile Diabetes Research Foundation International
Duration: Up to 3 years
Deadline: 27 October 2021
If you are interested on submitting a proposal, contact with scambray(ELIMINAR)@irblleida.cat